Immunovia intends to launch the new test by 2025 in the US. Credit: mi_viri / Shutterstock.

Immunovia has filed a provisional patent application in the US to protect its test designed to detect stage I and II pancreatic ductal adenocarcinoma (PDAC).

The patent application encompasses methods of diagnosing PDAC using a unique combination of five specific biomarkers and the process for interpreting these biomarkers to deliver test results.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The application was submitted to the US Patent and Trademark Office (USPTO), marking the first step in commercialising the company’s new test in the country.

Immunovia anticipates submitting additional clinical data to the USPTO in the coming months to strengthen its patent claim.

Furthermore, the company intends to file a single Patent Cooperation Treaty (PCT) application within the next year.

This strategic move would allow the company to seek broad international patent protection for its invention simultaneously in numerous countries.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

After this, Immunovia will target patents in specific high-value commercial markets outside the US.

Immunovia earlier announced the completion of its next-generation test for detecting stage 1 and 2 pancreatic cancer.

The company plans to undertake a large, independent clinical validation study to verify the test’s accuracy, in the fourth quarter of 2024.

If successful, Immunovia intends to launch the new test next year in the US.

Immunovia CEO Jeff Borcherding said: “Our scientists have invented a breakthrough approach to detecting pancreatic cancer and it’s vital we protect that invention.”

Immunovia is engaged in the development and commercialisation of simple blood-based testing to detect antibodies and proteins that indicate a high-risk individual has developed pancreatic cancer.